Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled time : 14:01 save search
I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting
Published: 2021-03-11 (Crawled : 14:01) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 3.05%
H: 3.72%
C: 3.72%
cancer antibody research preclinical pre-clinical
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium -- Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers
Published: 2021-01-16 (Crawled : 14:01) - ir.anaptysbio.com
ANAB | $19.865 0.18% 0.18% 290K
|
Health Technology
| Email alert
Add to watchlist
test positive cancer gastrointestinal symposium dostarlimab
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
Published: 2021-03-01 (Crawled : 14:01) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 6.38%
H: 0.57%
C: -2.0%
cancer license
Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia
Published: 2021-02-02 (Crawled : 14:01) - globenewswire.com
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: 65.38%
H: 0.58%
C: -27.33%
collaboration cancer treatment research art27.13
Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibitor Therapies
Published: 2021-01-19 (Crawled : 14:01) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 4.43%
H: 1.19%
C: -4.4%
positive endocrine cancer breast cancer hormone therapy metastatic breast cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.